Rhythm Pharmaceuticals, Inc.
RYTM
주식 순위
#3009
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial... Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
주가
$88.46
시가총액
$6.09B
변동 (1일)
-1.93%
변동 (1년)
-17.45%
국가
US
거래 Rhythm Pharmaceuticals, Inc. (RYTM)
카테고리
Healthcare
Rhythm Pharmaceuticals, Inc. (RYTM)의 주가 이력
최고 종가: $89.50 (2026-10-01 기준)
최저 종가: $24.67 (2017-10-01 기준)
최저 종가: $24.67 (2017-10-01 기준)
Rhythm Pharmaceuticals, Inc.의 주가 이력 (2017 ~ 2026)
연간 주가 성과
| 연도 | 성과 |
|---|---|
| 2026 (TTM) | -8.85% |
| 2025 | 91.54% |
| 2024 | 34.76% |
| 2023 | 48.81% |
| 2022 | 174.77% |
| 2021 | -64.82% |
| 2020 | 24.27% |
| 2019 | -12.59% |
| 2018 | -6.07% |
| 2017 | 0.00% |
유사 기업 또는 경쟁사의 주가
| 회사 | 주가 | 변동률 1년% | 국가 |
|---|---|---|---|
| $527.18 | 23.67% |
US
|
|
| $251.29 | 814.11% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $890.85 | 6.72% |
NL
|
|
| $752.87 | 7.40% |
CH
|
